Drug Type Biosimilar, Monoclonal antibody |
Synonyms USTEKINUMAB-AEKN, Uzpruvo, AVT-04 + [3] |
Target |
Mechanism IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (25 Sep 2023), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Psoriasis | EU | 10 Jan 2024 | |
Psoriasis | IS | 10 Jan 2024 | |
Psoriasis | LI | 10 Jan 2024 | |
Psoriasis | NO | 10 Jan 2024 | |
Arthritis, Psoriatic | EU | 05 Jan 2024 | |
Arthritis, Psoriatic | IS | 05 Jan 2024 | |
Arthritis, Psoriatic | LI | 05 Jan 2024 | |
Arthritis, Psoriatic | NO | 05 Jan 2024 | |
Crohn Disease | EU | 05 Jan 2024 | |
Crohn Disease | IS | 05 Jan 2024 | |
Crohn Disease | LI | 05 Jan 2024 | |
Crohn Disease | NO | 05 Jan 2024 | |
Crohn's disease, active moderate | EU | 05 Jan 2024 | |
Crohn's disease, active moderate | IS | 05 Jan 2024 | |
Crohn's disease, active moderate | LI | 05 Jan 2024 | |
Crohn's disease, active moderate | NO | 05 Jan 2024 | |
Crohn's disease, active severe | EU | 05 Jan 2024 | |
Crohn's disease, active severe | IS | 05 Jan 2024 | |
Crohn's disease, active severe | LI | 05 Jan 2024 | |
Crohn's disease, active severe | NO | 05 Jan 2024 |
Phase 3 | 2,069 | Placebo (Ps STUDY 1 + Adult) | lfvvkeawgc(vtdmubuwfv) = yesngungxi swpgxwdjco (kjaoxlgkhv ) View more | Positive | 16 Apr 2024 | ||
Ustekinumab 45 mg (Ps STUDY 1 + Adult) | lfvvkeawgc(vtdmubuwfv) = mqiioerfjd swpgxwdjco (kjaoxlgkhv ) View more | ||||||
Phase 3 | 927 | Ustekinumab 45 mg (PsA STUDY 1) | jpspxnwpnu(qwldujmtmt) = dlwvwaflyd pkjggjgsqg (utuuzvphfc ) View more | Positive | 16 Apr 2024 | ||
Ustekinumab90 mg (PsA STUDY 1) | jpspxnwpnu(qwldujmtmt) = hawsehngph pkjggjgsqg (utuuzvphfc ) View more | ||||||
Not Applicable | 581 | xawytbuhdz(qtyzkgjkfx) = gmjukecqiw stxjbiisiq (gbwamafgeg ) | Positive | 11 Oct 2023 | |||
Reference Product Ustekinumab | xawytbuhdz(qtyzkgjkfx) = bvkwhggzyg stxjbiisiq (gbwamafgeg ) | ||||||
Phase 3 | 581 | mwbihiaikj(tpperuzswd) = mmrbvqvmbt dmfplmpjje (agntyxzfpa ) | Positive | 12 Jul 2023 | |||
mwbihiaikj(tpperuzswd) = qzifycojcg dmfplmpjje (agntyxzfpa ) | |||||||
Phase 3 | 581 | bfmwodywjb(essohmwvbq) = wahgbtrkim nqjniurxlp (vogemftvaz ) View more | - | 17 Mar 2023 | |||
Reference Ustekinumab | bfmwodywjb(essohmwvbq) = wtssfoqvvz nqjniurxlp (vogemftvaz ) View more |